Incorporated

Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED reports fourth-quarter revenue of $2.07 billion, compared to Street Est’s $2.007 billion

By Patricia R. Gomez






Newswires MT 2022

All the news from VERTEX PHARMACEUTICALS

Analyst recommendations on VERTEX PHARMACEUTICALS

Sales 2021 7,502 million
–
–
Net income 2021 2,295 million
–
–
Net cash 2021 8,192 million
–
–
PER 2021 ratio 25.8x
2021 performance –
Capitalization 57,743 million
57,743 million
–
EV / Sales 2021 6.61x
EV / Sales 2022 5.57x
# of employees 3,400
Floating –

Chart VERTEX PHARMACEUTICALS


Duration :

Period :




Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener

Technical Analysis Trends VERTEX PHARMACEUTICALS

Short term Middle term Long term
Tendencies Bullish Bullish Bullish



Evolution of the income statement

To sell

To buy
Medium consensus SURPASS
Number of analysts 27
Last closing price

$227.11

Average target price

$268.39

Average Spread / Target 18.2%


Related posts:

  1. Funai Soken Incorporated: Notice regarding our request for selection in the new market category (main market)
  2. II-VI Incorporated (NASDAQ: IIVI) Achieves Consensus Brokerage Buy Rating
  3. Cantor Fitzgerald comments on Insmed Incorporated’s earnings for fiscal 2022 (NASDAQ: INSM)
  4. Conduent Incorporated (NASDAQ: CNDT) Given the average rating of “Conserve” by analysts
Patricia R. Gomez
You might also like More from author

Comments are closed.